hide message

Welcome to the Resource Centre

We make it our mission to work with advocates in civil society, business and government to address inequalities of power, seek remedy for abuse, and ensure protection of people and planet.

Both companies and impacted communities thank us for the resources and support we provide.

This is only possible because of your support. Please make a donation today.

Thank you,
Phil Bloomer, Executive Director

Donate now hide message

You are being redirected to the story the piece of content is found in so you can read it in context. Please click the following link if you are not automatically redirected within a couple seconds:

[PDF] Increasing people’s access to essential medicines in developing countries: a framework for good practice in the pharmaceutical industry

Author: UK Department for International Development (DFID), Published on: 1 March 2005

Responsibility for increasing access to essential medicines rests with the whole international community...In this context there is a particular role for pharmaceutical companies. As the producers of existing, and developers of new, medicines they can – and do – make a difference within their sphere of influence. [refers to Novartis, GlaxoSmithKline, Merck, Roche, Ranbaxy Laboratories, AstraZeneca, Tibotec (part of Johnson & Johnson), Eli Lilly, Pfizer, Shire Pharmaceuticals]

Read the full post here

Related companies: AstraZeneca Eli Lilly GlaxoSmithKline Johnson & Johnson Merck Novartis Pfizer Ranbaxy Laboratories Roche Shire Tibotec (part of Johnson & Johnson)